Date: Mar 17, 2015 Source: Reuters (
click here to go to the source)
 |
Celldex Therapeutics, Inc:Enters into clinical trial collaboration with Roche to evaluate safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting investigational antibody, and MPDL3280A (anti-PDL1).Says Varlilumab and MPDL3280A are part of new class of investigational medicines known as cancer immunotherapies.Says these are designed to harness body's own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.Celldex's Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, including a durable partial response that has continued to decrease in tumor volume over time and prolonged stable disease.Under terms of this agreement, Roche will provide study drug and Celldex will be responsible for conducting and funding the study, which is expected to begin in 2015.
